A photo of Lubov Timchenko.

Professor, UC Department of Pediatrics


Biography & Affiliation


Lubov Timchenko, PhD, is a professor in the UC Department of Pediatrics and a member of the Division of Neurology at Cincinnati Children’s Hospital Medical Center.

Dr. Lubov Timchenko received her PhD degree from St. Petersburg Institute of Experimental Medicine in St. Petersburg, Russia. She received post-doctoral training in molecular and human genetics at Baylor College of Medicine in Houston. Since 1995 until 2014, she was a faculty member at Baylor College of Medicine, working on the molecular mechanisms of neuro-muscular disorders, including myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).

In 2014, Dr. Timchenko joined the Department of Pediatrics at the University of Cincinnati and the Division of Neurology at Cincinnati Children's. Dr. Timchenko is internationally known for her contribution to several fundamental discoveries associated with the identification of a new family of RNA-binding proteins, CUGBP (also known as CUGBP and elav-like proteins, CELF), which play a significant role in the development and function of many tissues, including skeletal muscle, heart, brain and liver. Her studies showed that the proteins of this family regulate proliferation and differentiation in myogenesis and in liver cancer. The functional studies of the member of CUGBP protein family, CUGBP1, in myotonic dystrophy led to the discovery of a novel pathogenic mechanism by which non-coding RNAs cause neuro-muscular diseases. Recent work from Dr. Timchenko’s lab has suggested a new direction for therapy for adult and congenital myotonic dystrophy type 1.

Dr. Timchenko is a recipient of the prestigious Dr. Michael DeBakey’s Excellence in Research award for the outstanding contribution to biomedical research from Baylor College of Medicine. She has served on multiple national and international review boards at the National Institute of Arthritis, Skeletal Muscle and Skin Disorders, National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Association, French Muscular Association, Italian Telethon and others.

Clinical Interests

Congenital myotonic dystrophy; adult myotonic dystrophy type 1; myotonic dystrophy type 2; FXTAS

Research Interests

Molecular pathobiology and development of therapies for adult and congenital forms of neuro-muscular disease myotonic dystrophy type 1 and myotonic dystrophy type 2; the role of toxic RNAs containing long repeats in regulation of gene expression; skeletal muscle

Academic Affiliation

Professor, UC Department of Pediatrics




PhD: St-Petersburg Institute of Experimental Medicine, St. Petersburg, Russia, 1983.

Post-doctoral training: Department of Molecular Genetics, Baylor College of Medicine, Houston, TX, 1992-1995.


Correction of RNA-binding protein CUGBP1 and gsk3β signaling as therapeutic approach for congenital and adult myotonic dystrophy type 1. Timchenko, L. International Journal of Molecular Sciences. 2020; 21:94-94.

Correction of glycogen synthase kinase 3β in myotonic dystrophy 1 reduces the mutant RNA and improves postnatal survival of DMSXL mice. Wang, M; Weng, W; Stock, L; Lindquist, D; Martinez, A; Gourdon, G; Timchenko, N; Snape, M; Timchenko, L. Molecular and Cellular Biology. 2019; 39.

Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy. Wei, C; Stock, L; Schneider-Gold, C; Sommer, C; Timchenko, NA; Timchenko, L. Molecular and Cellular Biology. 2018; 38.

Correction of GSK3 beta at young age prevents muscle pathology in mice with myotonic dystrophy type 1. Wei, C; Stock, L; Valanejad, L; Zalewski, ZA; Karns, R; Puymirat, J; Nelson, D; Witte, D; Woodgett, J; Timchenko, NA; et al. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018; 32:2073-2085.

FXR-Gankyrin axis is involved in development of pediatric liver cancer. Valanejad, L; Lewis, K; Wright, M; Jiang, Y; D'Souza, A; Karns, R; Sheridan, R; Gupta, A; Bove, K; Witte, D; et al. Carcinogenesis. 2017; 38:738-747.

Subtly Modulating Glycogen Synthase Kinase 3 beta: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Palomo, V; Perez, DI; Roca, C; Anderson, C; Rodriguez-Muela, N; Perez, C; Morales-Garcia, JA; Reyes, JA; Campillo, NE; Perez-Castillo, AM; et al. Journal of Medicinal Chemistry. 2017; 60:4983-5001.

Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Tajhya, RB; Hu, X; Tanner, MR; Huq, R; Kongchan, N; Neilson, JR; Rodney, GG; Horrigan, FT; Timchenko, LT; Beeton, C. Cell Death and Disease. 2016; 7:e2426-e2426.

Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease. Jin, J; Valanejad, L; Nguyen, TP; Lewis, K; Wright, M; Cast, A; Stock, L; Timchenko, L; Timchenko, NA. Cell Reports. 2016; 16:744-756.

p300 Regulates Liver Functions by Controlling p53 and C/EBP Family Proteins through Multiple Signaling Pathways. Breaux, M; Lewis, K; Valanejad, L; Iakova, P; Chen, F; Mo, Q; Medrano, E; Timchenko, L; Timchenkoc, N. Molecular and Cellular Biology. 2015; 35:3005-3016.

Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5. Jones, K; Wei, C; Schoser, B; Meola, G; Timchenko, N; Timchenko, L. Proceedings of the National Academy of Sciences of USA. 2015; 112:8041-8045.